Literature DB >> 29327178

Clinical Impact and Risk Factors for Skeletal Muscle Loss After Complete Resection of Early Non-small Cell Lung Cancer.

Shinkichi Takamori1, Gouji Toyokawa2, Tatsuro Okamoto1, Mototsugu Shimokawa3, Fumihiko Kinoshita1, Yuka Kozuma1, Taichi Matsubara1, Naoki Haratake1, Takaki Akamine1, Kazuki Takada1, Masakazu Katsura1, Fumihiko Hirai1, Fumihiro Shoji1, Tetsuzo Tagawa1, Yoshinao Oda4, Hiroshi Honda5, Yoshihiko Maehara1.   

Abstract

BACKGROUND: A relationship between sarcopenia diagnosed by skeletal muscle area (SMA) and poor prognosis in cancer patients has recently been reported. This study aimed to clarify the clinical significance of postoperatively decreased SMA in patients with early non-small cell lung cancer (NSCLC).
METHODS: This study selected 101 patients with pathologic stage 1 NSCLC who had undergone pre- and postoperative (~ 1 year) computed tomography scans and lobectomy between 2005 and 2010 at Kyushu University Hospital. The post/pre ratio was defined as the postoperative normalized SMA (cm2/m2) at the 12th thoracic vertebra level divided by the preoperative normalized SMA. The cutoff value for the post/pre ratio was set at 0.9.
RESULTS: The study classified 31 patients (30.7%) as having decreased SMA. Poor performance status (PS) was significantly associated with decreased SMA (p = 0.048). The patients with decreased SMA had a significantly shorter disease-free survival (DFS) (p < 0.001) and overall survival (OS) (p < 0.001) than the other patients. Decreased SMA was found to be an independent prognostic factor for DFS (p = 0.010) and OS (p = 0.0072). The independent risk factors for skeletal muscle loss included poor PS (PS ≥ 1) and obstructive ventilatory impairment [forced expiratory volume (FEV) 1% < 70%].
CONCLUSIONS: Skeletal muscle loss after surgery is significantly associated with postoperative poor outcomes for patients with early NSCLC. Patients with poor PS, obstructive ventilatory impairment, or both need careful support to maintain their skeletal muscle mass. Future prospective studies may clarify whether physical activity and nutritional support improve postoperative prognosis.

Entities:  

Mesh:

Year:  2018        PMID: 29327178     DOI: 10.1245/s10434-017-6328-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

1.  Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A).

Authors:  Shun Sasaki; Eiji Oki; Hiroshi Saeki; Takayuki Shimose; Sanae Sakamoto; Qingjiang Hu; Kensuke Kudo; Yasuo Tsuda; Yuichiro Nakashima; Koji Ando; Yoshito Akagi; Yoshihiro Kakeji; Hideo Baba; Yoshihiko Maehara
Journal:  Int J Clin Oncol       Date:  2019-05-06       Impact factor: 3.402

2.  Sarcopenia in resected non-small cell lung cancer: let's move to patient-directed strategies.

Authors:  Philippe Icard; Antonio Iannelli; Hubert Lincet; Marco Alifano
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 3.  Optimizing health before elective thoracic surgery: systematic review of modifiable risk factors and opportunities for health services research.

Authors:  Sean M Stokes; Elliot Wakeam; Mara B Antonoff; Leah M Backhus; Robert A Meguid; David Odell; Thomas K Varghese
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

4.  Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.

Authors:  Hiroki Ishihara; Toshio Takagi; Tsunenori Kondo; Hironori Fukuda; Kazuhiko Yoshida; Junpei Iizuka; Kazunari Tanabe
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

5.  Effect of progressive sarcopenia during postoperative 6 months on long-term prognosis of completely resected lung cancer.

Authors:  Masashi Nagata; Hiroyuki Ito; Tomoyuki Yokose; Akihiro Tokushige; Shinichiro Ueda; Haruhiko Nakayama
Journal:  J Thorac Dis       Date:  2019-08       Impact factor: 2.895

6.  The oestrous cycle and skeletal muscle atrophy: Investigations in rodent models of muscle loss.

Authors:  Megan E Rosa-Caldwell; Marie Mortreux; Ursula B Kaiser; Dong-Min Sung; Mary L Bouxsein; Kirsten R Dunlap; Nicholas P Greene; Seward B Rutkove
Journal:  Exp Physiol       Date:  2021-10-18       Impact factor: 2.858

7.  Factors That Improve Chest Computed Tomography-Defined Sarcopenia Prognosis in Advanced Non-Small Cell Lung Cancer.

Authors:  Ming Yang; Lingling Tan; Lingling Xie; Song Hu; Dan Liu; Jing Wang; Weimin Li
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

8.  Risk factors for progressive sarcopenia 6 months after complete resection of lung cancer: what can thoracic surgeons do against sarcopenia?

Authors:  Masashi Nagata; Hiroyuki Ito; Tetsuo Yoshida; Akihiro Tokushige; Shinichiro Ueda; Tomoyuki Yokose; Haruhiko Nakayama
Journal:  J Thorac Dis       Date:  2020-03       Impact factor: 3.005

9.  Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage.

Authors:  Philippe Icard; Olivier Schussler; Mauro Loi; Antonio Bobbio; Audrey Mansuet Lupo; Marie Wislez; Antonio Iannelli; Ludovic Fournel; Diane Damotte; Marco Alifano
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

10.  Impact and risk factors for skeletal muscle mass loss after hepatic resection in patients with hepatocellular carcinoma.

Authors:  Shinji Itoh; Tomoharu Yoshizumi; Takahiro Tomiyama; Norifumi Iseda; Akinari Morinaga; Tomonari Shimagaki; Huanlin Wang; Takeshi Kurihara; Yoshihiro Nagao; Takeo Toshima; Noboru Harada; Akihiro Nishie; Kousei Ishigami; Masaki Mori
Journal:  JGH Open       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.